On August 4, 2026, the Sullivan Summit 2026 was grandly held at Shangri-La Shanghai Jing'an. Coinciding with the event, a celebration dinner was held to mark the 65th anniversary of Sullivan Global and the 20th anniversary of the S Sullivan Summit in China. The 2026 S Sullivan Global Awards and China Awards were announced at this event.
The event attracted a large number of guests, creating a lively atmosphere. There were leaders from management associations, experts from academic societies, representatives from investment and financing circles, leaders from leading enterprises in the industry, media figures, and scholars and experts from higher education institutions. Everyone gathered together to celebrate this event.
Regarding S Sullivan Best Practice Awards
The S Sullivan Growth, Innovation & Leadership Best Practice Awards (referred to as GIL Awards) aim to recognize outstanding enterprises that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of these awards have been widely recognized by the investment and financial communities as well as within the industry. So far, over 5,000 outstanding enterprises have been recognized globally.
The GIL Awards cover more than 20 countries and regions, directly connecting with the world’s top 1,000 enterprises and industry leaders. The award information is disseminated in multiple languages through a network of over 100 global media outlets, providing strong brand support for enterprises' internationalization efforts.
2026 marks the 65th anniversary of S Sullivan Global. During this year, S Sullivan China continuously studied numerous entrepreneurial and investment success cases in high-tech and strategic emerging industries. Through objective analysis and comprehensive evaluation, the innovation capabilities, business models, founding teams, technical capabilities, and development prospects of the participating enterprises were assessed. Together with a professional review committee, many outstanding biotech leading enterprises were finally selected.
Award ceremony at the event
Medical enterprises that won the 2026 S Sullivan GIL Global Award include: Beijing Gene Qiming Biotech Co., Ltd., Chengdu Shibekang Biopharmaceutical Technology Co., Ltd., Guangzhou Paizhen Biotechnology Co., Ltd., Hangzhou Nuanxinjia Electronic Technology Co., Ltd., Hangzhou Xuzhi Shi Technology Co., Ltd., Jiehua Biotechnology (Qingdao) Co., Ltd., Jilin Jumei Biotech Co., Ltd.,Lingke Pharmaceutical Co., Ltd.(Zhejiang) Co., Ltd., US BHF Reproductive Center, Pulo Pharmaceutical Co., Ltd., Shanghai Junsei Biotech Co., Ltd., Shanghai Yinghe Yimai Intelligent Technology Co., Ltd., Shenzhen Saiqiao Biotech Innovation Technology Co., Ltd.
Prof. Vinod K. Aggarwal, Global Chief Economist of S Sullivan, Distinguished Professor at UC Berkeley, and Director of APEC Research Center; Dr. Hu Jiguang, Member of S Sullivan Growth Strategy Expert Committee and Vice President of China at Morgan Stanley, gave the awardsBeijing Gene Qiming Biotech Co., Ltd.Award ceremony
Beijing Gene Qiming Biotech Co., Ltd. is the world’s leading company in the field of iNKT cell drugs.Established in 2015 in Beijing, Beijing Gene Qiming Biotech Co., Ltd. is the only company worldwide with a full spectrum of products.iNKT Cellslayout. The company has established a complete research, production, and clinical system, built a world-leading iNKT cell pilot platform, and holds exclusive and self-controlled core technologies for cell expansion and subpopulation regulation. It has received several international innovation awards.
As a national high-tech, specialized, and innovative enterprise, it led the development of the first group standard for iNKT cell industry. It has obtained 7 NMPA registration clinical approvals, covering areas such as cancer, autoimmunity, and severe respiratory diseases. It was the first in the world to verify the efficacy of iNKT cell therapy for liver cancer, and many products have achieved global breakthroughs. The company has completed an industrial transition from zero to one in the iNKT cell field, reshaping the global cell therapy industry landscape.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Meng Yi, Chair of S Sullivan Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking China, gave the awardsChengdu Shibekang Biopharmaceutical Technology Co., Ltd.Award ceremony.
Chengdu Shibekang Biopharmaceutical Technology Co., Ltd. is the world’scardio-cerebrovascularand respiratory new drug research and development leading company.Shibekang adheres to the mission of "giving care to all, enhancing health for everyone", and follows the values of "people-oriented, innovation-driven, and innovation supreme". Oriented towards clinical needs, it maintains a differentiated research and development strategy, focuses on cardio-cerebrovascular and respiratory diseases, and aims to become a world-class leader in differentiated innovation in new drugs, developing better medicines to benefit all people and protect human health.
Prof. Vinod K. Aggarwal, Global Chief Economist of S Sullivan, Distinguished Professor at UC Berkeley, and Director of APEC Research Center; Dr. Liu Jun, Chairman of SunoTech, Member of S Sullivan Specialized Committee on Specialized and Innovative Enterprises, gave the awardsGuangzhou Paizhen Biotechnology Co., Ltd.Award ceremony.
Guangzhou Paizhen Biotechnology Co., Ltd. is a leading technology innovation company in the field of gene therapy CRDMO.Founded in 2014, Paizhen Biotech aims to make gene therapy affordable for ordinary people. By using advanced vector technology and one-stop services, it seeks to accelerate the adoption of gene therapy, a transformative treatment, around the world. Facing the huge clinical potential of AAV vector therapy, as well as the high costs and technical barriers of traditional methods, Paizhen Biotech focuses on driving the industrialization of AAV production through fundamental technological innovation, making high-quality, large-scale, and cost-effective production possible.CGTfield. It has turned high-quality, large-scale, and economically efficient production into reality.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Meng Yi, Chair of S Sullivan Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking China, gave the awardsHangzhou Nuanxinjia Electronic Technology Co., Ltd.Award ceremony
Hangzhou Nuanxinjia Electronic Technology Co., Ltd. is the world’svisual brain-computerleading company.Nuanxinjia Technology has a 2,000-square-meter GMP-owned workshop with high-precision medical device production capabilities. Its products cover multiple lines such as visual brain-computer interfaces and neural regulation, and it has established several R&D subsidiaries at home and abroad, forming a global collaborative innovation network. In May 2026, the company successfully completed a Chinese GCP clinical trial, achieving a visual reconstruction breakthrough where patients can recognize complex letters the day after setup, potentially helping them restore functional vision and enable independent living. As a founding member of the National Brain-Computer Standards Committee, Nuanxinjia Technology has participated in the formulation of national brain-computer interface standards led by ministries such as the National Health Commission, Ministry of Industry and Information Technology, and the State Administration for Market Regulation, contributing to the rapid development of China’s brain-computer interface industry.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Meng Yi, Chair of S Sullivan Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking China, gave the awardsHangzhou Xuzhi Shi Technology Co., Ltd.Award ceremony.
Hangzhou Xuzhi Shi Technology Co., Ltd. (NEUREAL) is a national specialized and innovative “little giant” enterprise focused on non-invasive brain-computer interfaces (BCI).Focusing on “emotional brain-computer” technology, the company specializes in emotional and cognitive decoding, applying cutting-edge technologies such as AI, brain-computer interfaces, VR, DCBT, and tDCS in clinical settings, serving individuals with brain disorders such as depression, ADHD, autism, and cognitive decline. It covers three scenarios: hospital clinical use, adolescent psychological intervention, and home brain health care. By decoding emotions and cognition, the company improves brain health.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Meng Yi, Chair of S Sullivan Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking China, gave the awardsJiehua Biotechnology (Qingdao) Co., Ltd.Award ceremony
Jiehua Biotechnology (Qingdao) Co., Ltd. is a leading technology innovation company in the field of large molecular new drugs.With over twenty years of research and development experience in biological new drugs, Jiehua Biotech has established a complete biopharmaceutical technology chain from laboratory development of novel large molecular proteins to large-scale industrial production. It has the technical capacity to continuously innovate and produce original biological large molecules.
Dr. Bin Shunjie, Global Senior Vice President, Asia-Pacific Co-Chair, Chairman of China, and Senior Advisor to S Sullivan, Business Partner of Ernst & Young in China, gave the awardsJilin Jumei Biotech Co., Ltd.Award ceremony.
Jilin Jumei Biotech Co., Ltd. is the world’s leading company in humanized recombinant full-spectrum collagen anti-aging products.Established in September 2024, Jilin Jumei Biotech is located in Jiaohe City, Jilin Province. It is the first domestic enterprise to achieve large-scale production of “humanized recombinant collagen-elastic protein dual proteins”. It has achieved the world’s first ton-level production of humanized elastic proteins. Using gene recombination and fermentation purification technology platforms, the company has built a 6,400-square-meter GMP facility capable of producing 5 million units of CLP/ELP preparations per year, providing safe, efficient, and green anti-aging solutions for small medical beauty institutions and individual consumers.
Prof. Vinod K. Aggarwal, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Prof. Wang Yu, Chairman of the China Hepatitis Prevention and Treatment Foundation, former Director of the Chinese Center for Disease Control and Prevention, gave the awardsLingke Pharmaceutical (Zhejiang) Co., Ltd.Award ceremony.
Lingke Pharmaceutical (Zhejiang) Co., Ltd. is the world’s leading company in the field of autoimmune and inflammatory small molecules.By developing innovative therapies, Lingke Pharmaceutical meets unmet clinical needs. It strives to benefit global patients through differentiated innovative therapies. So far, Lingke Pharmaceutical has developed several self-developed first-class clinical new drugs and has conducted multiple clinical trials globally, either independently or in collaboration with international partners.
Dr. Bin Shunjie, Global Senior Vice President, Asia-Pacific Co-Chair, Chairman of China, and President of Mass Transit Group, gave the awardsUS BHF Reproductive CenterAward ceremony.
US BHF Reproductive Center (Beverly Hills Fertility) received the S Sullivan Global Assisted Reproduction Market Leadership Award.As one of the few international reproductive centers in California, BHF is composed of renowned reproductive endocrinologists, infertility experts, embryology experts, and laboratory experts, with an average tenure of nearly 20 years.
BHF has laboratories certified by CLIA and CAP, and has passed the TJC certification, which is a high-standard review of medical quality and service levels in the United States. BHF has a fertilization rate of up to 97%, as well as high rates of embryo transfer and pregnancy success rates across all age groups, exceeding the world’s top laboratory benchmarks defined by the Vienna Consensus.
BHF adheres to the concept of personalized reproductive care, integrating cutting-edge genetic science, advanced embryonic laboratory technology, and big data analysis to optimize personalized reproductive medicine. It has become a designated partner hospital for women’s fertility services among many Fortune 500 companies.
Prof. Vinod K. Aggarwal, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Prof. Wang Yu, Chairman of the China Hepatitis Prevention and Treatment Foundation, former Director of the Chinese Center for Disease Control and Prevention, gave the awardsPulo Pharmaceutical Co., Ltd.Award ceremony
Pulo Pharmaceutical Co., Ltd. (000739.SZ) won the 2026 S Sullivan GIL “Global CDMO Annual Company Award”.The company specializes in integrated services for specialty raw materials and small molecule CDMOs. With seven raw material production bases (including chemical synthesis and biorefinement), two formulation factories, and products in advantageous treatment areas such as cardio-cerebrovascular, anti-infective, psychiatric, and anti-tumor fields, it has built a continuous, automated, digital, and intelligent pharmaceutical manufacturing and process development platform. Its quality system has passed official audits and inspections by China NMPA, US FDA, EUEMA/EDQM, and Japan PMDA, ensuring compliant market supply and full traceability across the entire chain. It continues to provide one-stop research and manufacturing services to domestic and international innovative pharmaceutical companies, CROs, and formulation enterprises.
Prof. Vinod K. Aggarwal, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Prof. Wang Yu, Chairman of the China Hepatitis Prevention and Treatment Foundation, former Director of the Chinese Center for Disease Control and Prevention, gave the awardsShanghai Junsei Biotech Co., Ltd.Award ceremony
Shanghai Junsei Biotech Co., Ltd. is the world’s leading company in the field of solid tumor cell therapy.With three proprietary technology platforms: DeepTIL™ cell expansion platform, NovaGMP™ gene modification technology platform, and RiverTIL™ endogenous TIL platform, the company enhances product efficacy and safety from the source, significantly reducing production and comprehensive treatment costs, and improving the accessibility of TIL therapy. Focusing on highly prevalent tumors and refractory tumors, the company has developed a series of globally first-in-class or best-in-class autologous natural TIL and gene-modified TIL products, covering early adjuvant therapy to late-stage treatment across multiple disease stages and treatment scenarios.
Prof. Vinod K. Aggarwal, Global President and Managing Partner, Global Board Executive Director of S Sullivan; Prof. Wang Yu, Chairman of the China Hepatitis Prevention and Treatment Foundation, former Director of the Chinese Center for Disease Control and Prevention, gave the awardsShanghai Yinghe Yimai Intelligent Technology Co., Ltd.Award ceremony
Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. is the world’s leading company in the field of medical imaging AGI.The company has deep medical and technical expertise. Its founding team members are top domestic and North American imaging medicine experts and big data & artificial intelligence experts, with rich management and research experience in imaging medicine, big data, and AI product development.
Based on its own globally leading cross-modal, full-process “Yinghe Miyu®” medical imaging base large model, the company creates full-chain imaging intelligent solutions, multi-modal agents (Agents), doctor digital duplics, and high-value medical imaging asset management platforms. By leveraging full-domain AI capabilities, it enhances clinical diagnosis and hospital management, redefines medical work efficiency, promotes digital, precise, and systematic upgrades in the medical industry, and builds the next-generation smart medical imaging AI ecosystem. In the future, it will expand its business scope globally.
Dr. Bin Shunjie, Global Senior Vice President, Asia-Pacific Co-Chair, Chairman of China, and President of Mass Transit Group, gave the awardsShenzhen Saiqiao Biotech Innovation Technology Co., Ltd.Award ceremony.
Shenzhen Saiqiao Biotech Innovation Technology Co., Ltd. is a leading technology innovation company in the field of CGT industry empowerment.The core team has been responsible for major national biInstrumentation projects. With over 10 years of experience in instrument engineering and bi-related technologies, it is one of the earliest specialized teams in China focusing on cell processing and automated equipment. With the vision of “no disease that cannot be treated”, Saiqiao Biotech focuses on the industry characteristics of “process as product, tools as process” in cell therapy, as well as the core pain points of “inability to deliver or high cost”. It works closely with industry customers to become one of the top three cell therapy tool platforms globally, covering early research, clinical, and commercial stages with fully independent intellectual property rights.
Medical enterprises that won the 2026 S Sullivan GIL China Award include: Fuxiang Shareholding Group, Pukang Biotech Technology (Shanghai) Co., Ltd., Shenzhen Zeyi Cell Therapy Group.
Georgia Edell, Global Chief Analyst of S Sullivan in Asia, and Diego Shimizu, Asian Analyst of S SullivanFuxiang Shareholding GroupAward ceremony.
Fuxiang Shareholding Group (300497.SZ) is a market leader in the field of synthetic bio-food proteins in China.Frost & Sullivan China actively expands into the field of synthetic biology to align with the global biotech industry trend. It has now become the first company in Asia to industrialize filamentous fungal proteins on a ton scale. Current main products include microbial proteins, amino acid-based water-soluble fertilizers, and other biofermentation products. Among these, microbial proteins feature high efficiency, low consumption, sustainability, and health benefits, aligning with national and local industrial development policies.
Frost & Sullivan Asia Chief Analyst Georgia Edell and Frost & Sullivan Asia Analyst Jihun Kang (Will)Fukang Biotechnology (Shanghai) Co., Ltd.Frost & Sullivan Awards Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo
Fukang Biotech (Shanghai) Co., Ltd. is a product innovation company in the field of cancer immunotherapy drugs in ChinaFrost & Sullivan focuses on developing cutting-edge treatment methods for cancer, while also advancing innovative drug research for viruses and age-related diseases. The company aims to offer multi-line treatment options and serve a broad patient population to drive rapid revenue growth. The company has adopted the PIP model in research, designing a single drug to cover multiple indications. This approach has successfully expanded the new indications of some candidate drugs, and it will further extend to common solid tumors such as respiratory, gastrointestinal, and urological conditions.
Frost & Sullivan Global Executive Board Member and Chief AI Architect Subhranshu Shekhar Das, along with Frost & Sullivan China Director and President Wang Chenhui, provided insightsShenzhen Zeyi Cell Therapy GroupFrost & Sullivan Awards Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo
Frost & Sullivan China is a market-leading company in the field of long-life medical services.Frost & Sullivan China, with the goal of enhancing healthy lifespan, has joined forces with Nobel laureates, academicians, and medical experts from home and abroad to launch the “Eternal Life Ark” program. They continue to explore scientific approaches that enable people to live longer, healthier, and more fulfilling lives, helping humans live happily until their natural end of life.
Based on Cell Technology as its core engine, it integrates life genomics, functional assessment, chronic disease management, and clinical translation, connecting research, healthcare, and health management to establish a full-lifecycle longevity medicine system covering risk identification, precise evaluation, proactive intervention, and long-term management, thereby promoting health services from treating existing diseases to proactive health promotion, comprehensive management, and increased healthy lifespan.
More exciting moments from the event
